At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 46 enrolled
Drug / intervention
Multihance +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IV Double-blind Multicenter Randomized Crossover Study to Compare 0.10 mmol/kg of Multihance With 0.10 mmol.kg of Magnevist in Magnetic Resonance Imaging(MRI) of the Brain at 3T
In Brief
A Phase 4 clinical trial evaluating Multihance and Arm 2 - Magnevist for Brain Tumor. Completed, enrolled 46 participants across 1 site.
Detailed Summary
Compare the efficacy of MultiHance and Magnevist
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBrain Tumor
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2006
First PostedNov 2006
Primary CompletionFeb 2008
Study CompletionMar 2008
TodayJul 2026
First PostedNov 6, 2006
Enrollment StartNov 1, 2006
Primary CompletionFeb 1, 2008
Study CompletionMar 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 19.7 years ago
Interventions
Multihancedrug
0.5 M at a single injection
Arm 2 - Magnevistdrug
0.5 M Magnevist at a single dose injection